| Title |
EGFR inhibitors and autophagy in cancer treatment
|
|---|---|
| Published in |
Tumor Biology, October 2014
|
| DOI | 10.1007/s13277-014-2660-z |
| Pubmed ID | |
| Authors |
Jie Cui, Yun-Feng Hu, Xie-Min Feng, Tao Tian, Ya-Huan Guo, Jun-Wei Ma, Ke-Jun Nan, Hong-Yi Zhang |
| Abstract |
Epidermal growth factor receptor (EGFR) inhibitor treatment is a strategy for cancer therapy. However, innate and acquired resistance is a major obstacle of the efficacy. Autophagy is a self-digesting process in cells, which is considered to be associated with anti-cancer drug resistance. The activation of EGFR can regulate autophagy through multiple signal pathways. EGFR inhibitors can induce autophagy, but the specific function of the induction of autophagy by EGFR inhibitors remains biphasic. On the one hand, autophagy induced by EGFR inhibitors acts as a cytoprotective response in cancer cells, and autophagy inhibitors can enhance the cytotoxic effects of EGFR inhibitors. On the other hand, a high level of autophagy after treatment of EGFR inhibitors can also result in autophagic cell death lacking features of apoptosis, and the combination of EGFR inhibitors with an autophagy inducer might be beneficial. Thus, autophagy regulation represents a promising approach for improving the efficacy of EGFR inhibitors in the treatment of cancer patients. |
Mendeley readers
The data shown below were compiled from readership statistics for 25 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 1 | 4% |
| Unknown | 24 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 6 | 24% |
| Other | 4 | 16% |
| Student > Ph. D. Student | 4 | 16% |
| Researcher | 3 | 12% |
| Student > Postgraduate | 2 | 8% |
| Other | 5 | 20% |
| Unknown | 1 | 4% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 7 | 28% |
| Medicine and Dentistry | 4 | 16% |
| Biochemistry, Genetics and Molecular Biology | 3 | 12% |
| Chemistry | 2 | 8% |
| Unspecified | 1 | 4% |
| Other | 2 | 8% |
| Unknown | 6 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 October 2014.
All research outputs
#14,788,263
of 22,768,097 outputs
Outputs from Tumor Biology
#969
of 2,622 outputs
Outputs of similar age
#140,800
of 255,209 outputs
Outputs of similar age from Tumor Biology
#33
of 134 outputs
Altmetric has tracked 22,768,097 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,622 research outputs from this source. They receive a mean Attention Score of 2.2. This one has gotten more attention than average, scoring higher than 60% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 255,209 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 42nd percentile – i.e., 42% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 134 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.